// App-Quantinova.ai

: ACTR-12. PHASE 2 STUDY OF DIANHYDROGALACTITOL (VAL-083) IN PATIENTS WITH MGMT-UNMETHYLATED, BEVACIZUMAB-NAÏVE GLIOBLASTOMA IN THE RECURRENT AND ADJUVANT SETTING

Researchers

Presenter

  • John Langlands

Principal Investigators

  • Richard Schwartz

  • Sarath Kanekal

  • Lorena Lopez

  • John deGroot

Medical Centers

  • Del Mar Pharmaceuticals, Vancouver, BC, Canada

  • DelMar Pharmaceuticals, Menlo Park, CA

Locations

  • Canada

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Glioblastoma

Biomarkers

  • N/A

Drug/Treatment

  • Dianhydrogalactitol

  • Temozolomide

  • Bevacizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02717962

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved